Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 36 citing articles:

Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
Xuetian Gao, Ling Peng, Li Zhang, et al.
Journal of Cancer Research and Clinical Oncology (2021) Vol. 148, Iss. 10, pp. 2661-2671
Closed Access | Times Cited: 10
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan
Ticiana Leal, Anandaroop Dasgupta, Dominick Latrémouille-Viau, et al.
JCO Global Oncology (2024), Iss. 10
Open Access | Times Cited: 1
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, et al.
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 7, pp. 805-812
Open Access | Times Cited: 1
Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study
Jia‐Yi Deng, Mingyi Yang, Xiaorong Yang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer
Qiao-xin Lin, Wen-Wen Song, Wenxia Xie, et al.
Neoplasia (2024) Vol. 59, pp. 101077-101077
Open Access | Times Cited: 1
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Tannaz Dehghani, Alireza Shahrjerdi, Mohammad Saeed Kahrizi, et al.
Pathology - Research and Practice (2023) Vol. 246, pp. 154470-154470
Closed Access | Times Cited: 3
Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma
Martin Metzenmacher, Filippo Rizzo, Kato Kambartel, et al.
Future Oncology (2021) Vol. 17, Iss. 30, pp. 3965-3976
Open Access | Times Cited: 7
Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy
Ticiana Leal, Mark A. Socinski
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 8, pp. 817-833
Open Access | Times Cited: 2
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis
Koichi Andō, Ryo Manabe, Yasunari Kishino, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 52-52
Open Access | Times Cited: 3
Identification of two cancer stem cell-like populations in triple-negative breast cancer xenografts
Jun Nakayama, Hiroko Matsunaga, Koji Arikawa, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 3
Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis
Jiaqi Li, Ying‐Jie Chen, Fan Hu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
Alastair Greystoke
Clinical Oncology (2022) Vol. 34, Iss. 7, pp. 469-471
Open Access
Antiangiogenic therapy in pretreated patients with lung adenocarcinoma without activating mutations: new features
Е. В. Реутова, К. К. Лактионов
Journal of Modern Oncology (2021) Vol. 23, Iss. 3, pp. 425-427
Open Access
Previous Page - Page 2

Scroll to top